Akari Therapeutics, Plc

NasdaqCM AKTX

Akari Therapeutics, Plc Dividends Paid for the year ending December 31, 2023: USD 0.00

Akari Therapeutics, Plc Dividends Paid is USD 0.00 for the year ending December 31, 2023, a 0.00% change year over year. Dividends paid is cash paid to shareholders as a distribution of profits.

Akari Therapeutics, Plc Dividends Paid for the year ending December 31, 2022 was USD 0.00, a 0.00% change year over year.
Akari Therapeutics, Plc Dividends Paid for the year ending December 31, 2021 was USD 0.00, a 0.00% change year over year.
Akari Therapeutics, Plc Dividends Paid for the year ending December 31, 2020 was USD 0.00, a 0.00% change year over year.
Akari Therapeutics, Plc Dividends Paid for the year ending December 31, 2019 was USD 0.00, a 0.00% change year over year.

Key data

Date	Dividends Paid	Capital Expenditure	Other Financing Activities	Net Cash Used Provided By Financing Activities

NasdaqCM: AKTX

Akari Therapeutics, Plc

CEO	Dr. Samir Rashmikant Patel M.D.
IPO Date	Jan. 6, 2014
Location	United Kingdom
Headquarters	75/76 Wimpole Street
Employees	6
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Key trends

Past 5 years